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Abstract: Mammographic breast density (MD) reflects breast fibroglandular content. Its decline following
adjuvant tamoxifen treated, estrogen receptor (ER)-positive breast cancer has been associated with
improved outcomes. Breast cancers arise from structures termed lobules, and lower MD is associated
with increased age-related lobule involution. We assessed whether pre-treatment involution influenced
associations between MD decline and risk of breast cancer-specific death. ER-positive tamoxifen treated
patients diagnosed at Kaiser Permanente Northwest (1990–2008) were defined as cases who died of breast
cancer (n = 54) and matched controls (remained alive over similar follow-up; n = 180). Lobule involution
was assessed by examining terminal duct lobular units (TDLUs) in benign tissues surrounding cancers
as TDLU count/mm2, median span and acini count/TDLU. MD (%) was measured in the unaffected
breast at baseline (median 6-months before) and follow-up (median 12-months after tamoxifen initiation).
TDLU measures and baseline MD were positively associated among controls (p < 0.05). In multivariable
regression models, MD decline (≥10%) was associated with reduced risk of breast cancer-specific death
before (odds ratio (OR): 0.41, 95% CI: 0.18–0.92) and after (OR: 0.41, 95% CI: 0.18–0.94) adjustment for
TDLU count/mm2, TDLU span (OR: 0.34, 95% CI: 0.14–0.84), and acini count/TDLU (OR: 0.33, 95%
CI: 0.13–0.81). MD decline following adjuvant tamoxifen is associated with reduced risk of breast
cancer-specific death, irrespective of pre-treatment lobule involution.
Keywords: breast cancer; mammographic breast density; involution; terminal duct lobular unit
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1. Introduction
Approximately 80% of breast cancers in the United States (US) are estrogen receptor
(ER)-positive and incidence rates are increasing [1]. Although treatment with the selective estrogen
receptor modulator (SERM) tamoxifen dramatically reduces mortality related to these cancers [2],
fatal recurrences occur at a rate of 1%–2% per year over a long-term follow-up of 15 years.
Accordingly, identifying women who are most likely to respond to tamoxifen treatment, at early stages
of their treatment, would improve clinical management.
High mammographic breast density (MD), which reflects the percentage of breast parenchyma
comprised of fibroglandular tissue, is associated with elevated breast cancer risk overall and
for ER-positive breast cancers [3,4]. We and others showed that women who experience MD
decline one year following initiation of adjuvant tamoxifen treatment have reduced risk of breast
cancer-specific mortality compared to women who do not experience a decline [5–8]. There are multiple
mechanisms proposed to modify the response to tamoxifen therapy, often leading to intrinsic or
acquired resistance [9]. Molecular characteristics of breast tumors that have been shown to influence
tamoxifen efficacy include crosstalk of growth factor signaling with ER signaling pathways as well
as upregulation of phosphoinositide-3-kinase/AKT signaling downstream of ERα [10]. In addition,
pharmacologic mechanisms related to drug activity also influence response to tamoxifen therapy.
Specifically, inter-individual differences in the capacity to convert the parent drug to its more active
metabolites may influence tamoxifen effectiveness [9]. It has been hypothesized that a decline in
MD may represent the activity of such metabolites. Further, at the histological level, treatment with
tamoxifen has shown to reduce stromal density [11] and epithelial mass [12] in rodents. Taken together,
these studies suggest that MD decline may represent a biosensor of treatment response.
The fibroglandular component of the breast is comprised of non-fatty stroma and terminal duct
lobular units (TDLUs), which include the majority of at risk epithelial cells [13]. TDLUs involute
with aging and are replaced by fatty tissue and collagen, processes that can be influenced by
reproductive factors including parity and menopause [14]. TDLUs have been described as a principal
source and location for breast cancer, and reduced levels of TDLU involution is associated with
increased risk of developing breast cancer among women diagnosed with benign breast disease [15–18].
Additionally, failure of lobule involution to progress among women who underwent benign biopsies
at two time points was linked to increased breast cancer risk compared with women who experience
age-related progressive lobule involution over time [19].
Both higher MD and reduced TDLU involution are global measures of breast cancer risk. As MD
decline is also associated with lower risk of breast cancer following tamoxifen therapy in the prevention
setting [20], it biologically plausible that the pre-treatment baseline level of lobule involution may
influence the associations observed between these two risk factors. Indeed, prior studies have shown
that there are moderate correlations between high MD and reduced TDLU involution [21,22].
Upon a diagnosis of breast cancer, little is known about the role of TDLU involution in tumor
progression and prognosis [23,24]. We hypothesize that the biological mechanisms underlying
improved breast cancer outcomes associated with MD decline may be influenced by the degree of
TDLU involution at diagnosis. Therefore, in this study we assess whether levels of TDLU involution in
benign tissues adjacent to breast cancers influence the relationship between MD decline and improved
breast cancer-specific survival among ER-positive breast cancer patients treated with tamoxifen in a
general community health care plan.
2. Methods
2.1. Study Population
Women in this study were part of a previously conducted case-control study designed to evaluate
the prognostic significance of MD change, as described in detail elsewhere [6]. That prior study included
349 patients who were selected from a cohort of 2315 Kaiser Permanente Northwest health care plan
J. Clin. Med. 2019, 8, 1868 3 of 15
(KPNW; Portland, OR, USA) members diagnosed with ER-positive primary invasive breast cancer of
localized or regional stage, between 1990 and 2008 and who were treated with adjuvant tamoxifen therapy.
Briefly, cases were patients who died of breast cancer during follow-up, through 31 December 2010; vital
status was ascertained from the KPNW tumor registry. The control population included breast cancer
patients who were alive at follow-up or had died from other causes but that had not died from breast
cancer as of the last tumor registry follow-up during the study period (31 December 2010). Control patients
were matched to each case on age at diagnosis, tumor stage and year of diagnosis, using the categories
outlined in more detail below, and were sampled to have at least as much follow-up time as the matched
case patient. Approval to carry out this study was obtained by the Special Studies Institutional Review
Board of the National Cancer Institute and the Institutional Review Board of KPNW.
Covariate data were obtained from electronic and paper medical records as previously described [6].
Data were categorized for analysis and included age at diagnosis, body mass index (BMI) at diagnosis,
race, smoking status, tumor stage at diagnosis, calendar year of diagnosis, progesterone receptor (PR)
status, tumor size and tumor grade. Prescription records and treatment data were obtained from
KPNW databases, including duration of tamoxifen use and menopausal hormone therapy use, [6].
2.2. Breast Tissue Collection
Available archived hematoxylin and eosin (H&E)-stained tissue sections from breast surgeries
related to the primary breast cancer diagnosis were reviewed by our study pathologist (MES) to assess
tumor pathology and the availability of adjacent non-tumor tissue sections suitable for analysis of
TDLU involution (Figure 1).
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TDLU measures.
2.3. TDLU Histologic Assessment
Digital whole-slide images of one representative H&E-stained breast tissue section from each
patient were generated at 20× magnification (Leica Aperio AT2, Vista, CA, USA) and compiled for
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web-based review and digital measurement/annotation (Leica Aperio Imagescope software v12.3; Vista,
CA, USA). Three independent standardized measurements of TDLU involution were assessed [25] by
the ASCP certified cyto-technician (RC). First, the number of normal TDLUs was visually counted and
standardized for tissue area (TDLU count/mm2). Second, the average TDLU span, i.e., the average
size in microns of the longest axis of up to 10 TDLUs, was determined [24]. Finally, the number of
acini per each TDLU was determined using a semi-automated image analysis tool [26]. Median values
for each patient were used as summary measures of TDLU span and acini count (i.e., median TDLU
span and median acini count/TDLU). To ensure reproducibility, a repeat assessment was carried out by
the study cyto-technician (RC) in a masked fashion on a subset of 50 H&E-stained tissue sections that
were selected using a stratified random sample approach across all age categories to ensure a wide
range of TDLU involution levels. Results from this reliability assessment showed strong intra-observer
agreement for each of the three TDLU measures, with intraclass correlation coefficients (ICCs) as
follows: TDLU counts = 0.85; median TDLU span = 0.81 and median acini count/TDLU = 0.92.
2.4. Mammographic Breast Density (MD) Assessment
Assessment of MD was carried out as previously described [6]. Briefly, baseline and follow-up
craniocaudal film mammographic views from the contralateral breast were obtained for each woman: a
median of 6 months prior to the initiation of tamoxifen initiation (baseline) and a median of 10.8 months
post-tamoxifen initiation (follow-up). The median time between baseline mammogram and follow-up
mammograms in this analytical population was 15.6 months (for case patients 15.4 months and for
control patients 15.6 months). Films were digitized using an Array Corporation 2095 Laser Film
Digitizer (Roden, the Netherlands; optical density = 4.0). Using Cumulus software [27], a single
reader (EAB) assessed mammographic images for absolute dense area (cm2) and total breast area (cm2).
High reproducibility of MD assessment was confirmed as previously described [6]. MD measurements
assessed in this analysis included absolute dense area (cm2), total breast area (cm2), non-dense area
(cm2) (total breast area–absolute dense area), percent density ((dense area/total breast area) × 100) and
percent MD density change (percent density at follow-up−percent density at baseline).
2.5. Statistical Analysis
Descriptive characteristics were compared between case patients and control patients using
chi-square Fisher exact, and Wilcoxon rank sum tests as appropriate. Univariate relationships between
patient and tumor characteristics and TDLU measurements were assessed using the Kruskal–Wallis
test. Relationships between TDLU measurements were evaluated using Spearman’s rank correlation
coefficients. To determine relationships between tertiles of TDLU measures and continuous MD
measures analysis of covariance (ANCOVA) models were used, adjusting for age, stage, year of
diagnosis and BMI. MD measures were square-root transformed to better approximate normal
distributions. For ease of interpretation, back transformed least square means, with calculated
corresponding 95% confidence intervals, are presented by tertiles of TDLU measures. Tertiles of TDLU
measures were defined according to distributions of measures among control patients.
We undertook two approaches to investigate the influence of TDLU metrics on the relationship
between MD decline and risk of breast cancer death: adjustment and stratification. In the former
approach, odds ratios (OR) and 95% confidence intervals (CI) for the association between MD decline of
10% or greater and breast cancer-specific death were estimated using unconditional logistic regression,
initially adjusting for matching factors only (age, stage and year of diagnosis) and case follow-up time,
and then additionally separately adjusting for each TDLU metric. Unconditional logistic regression
was used to retain statistical power given that not all cases and controls had tissue available for
TDLU analysis. The cut-point of 10% for MD decline was selected based on previously published
data showing that a decline of this magnitude has been consistently associated with improved breast
cancer outcomes in this and other study populations [5]. In the second approach, we evaluated the
association between MD decline and breast cancer-specific death in unconditional logistic regression
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models stratified by the median of each TDLU metric based on the distribution among control patients.
All statistical analyses were carried out using SAS 9.3 (SAS Institute Inc., Cary, NC, USA). p-values of
<0.05 were considered statistically significant and all tests were two-tailed.
3. Results
3.1. Characteristics of Study Population
Clinicopathological characteristics of the final study population are shown in Table 1.
Compared with control patients, case patients had tumors that were less frequently well-differentiated
or PR-positive. Case patients were more likely to be smokers and had a significantly shorter duration
of tamoxifen therapy (Table 1).
Table 1. Selected patient and tumor characteristics among ER-positive breast cancer patients treated
with tamoxifen with available adjacent normal tissue blocks for TDLU assessment.
All Patients Case Patients Control Patients Comparison of Case Patients
and Control Patients(n = 234) (n = 54) (n = 180)
Characteristic n % n % n % p Value $
Age at diagnosis (years) 0.20
<50 59 25.2 14 25.9 45 25.0
50–59 65 27.8 10 18.5 55 30.6
>59 110 47.0 30 55.6 80 44.4
Race 0.58*
White 229 97.9 175 97.2 54 100.0
Non-white 4 1.7 4 2.2 0 0.0
Missing 1 0.4 1 0.6 0 0.0
Smoking status at baseline 0.02
Never 128 54.7 22 40.7 106 58.9
Ever 106 45.3 32 59.3 74 41.1
BMI at diagnosis (kg/m2) 0.16
<25 72 30.8 11 20.4 61 33.9
25 to <30 64 27.4 16 29.6 48 26.7
≥30 67 28.6 19 35.2 48 26.7
Missing 31 13.2 8 14.8 23 12.8
Hormone therapy use at baseline 0.79
Non-user 92 39.3 22 40.7 70 38.9
Current user 104 44.4 22 40.7 82 45.6
Former user 38 16.2 10 18.5 28 15.6
SEER summary stage at diagnosis 0.90
Localized 98 41.9 23 42.6 75 41.7
Regional/distant/unknown 136 58.1 31 57.4 105 58.3
Year of diagnosis 0.16
1990–1996 93 39.7 23 42.6 70 38.9
1997–2000 79 33.8 22 40.7 57 31.7
2001–2008 62 26.5 9 16.7 53 29.4
Progesterone receptor 0.02
Negative 48 20.5 17 31.5 31 17.2
Positive 185 79.1 37 68.5 148 82.2
Missing 1 0.4 0 0.0 1 0.6
Tumor size (mm) 0.08
≤2 141 60.3 26 48.1 115 63.9
>2 84 35.9 24 44.4 60 33.3
Missing 9 3.8 4 7.4 5 2.8
J. Clin. Med. 2019, 8, 1868 6 of 15
Table 1. Cont.
All Patients Case Patients Control Patients Comparison of Case Patients
and Control Patients(n = 234) (n = 54) (n = 180)
Characteristic n % n % n % p Value $
Tumor differentiation <0.01 *
Well differentiated 44 18.8 1 1.9 43 23.9
Moderately differentiated 123 52.6 32 59.3 91 50.6
Poorly differentiated 54 23.1 17 31.5 37 20.6
Missing 13 5.6 4 7.4 9 5.0
Duration of tamoxifen use (months)
Mean (SD) 50.4 (19.9) 42.6 (20.3) 52.7 (19.3) <0.01 #
$ Chi-Squared analysis; * Fisher exact test; # Wilcoxon rank sum test; p-Values <0.05 are highlighted in bold font.
Descriptive statistics comparing the demographic and clinical characteristics of the original
case-control patient population [6] with the final current study population with available adjacent
normal tissue blocks for TDLU assessment, overall and by case-control status, are shown in
Supplementary Table S1A,B, respectively. Overall 54 cases (56% of the original case-set within
the case-control study [6]) and 180 control (71% of the original control set from the case-control
study [6]) patients had tissue available for analysis. Compared with patients with available benign
tissues, those whose tissues were unavailable were more likely to have died from breast cancer
(Supplementary Table S1A). Similar case-control differences were observed for patients with and
without available benign tissues (Supplementary Table S1B).
3.2. Relationships between Participant Characteristics and TDLU Measurements
TDLUs were observed in 95% of cases and 89% of controls. TDLU count/mm2 was modestly
correlated with TDLU span and acini count/TDLU, while TDLU span and acini count/TDLU were
strongly correlated with each other (Supplementary Table S2). The relationships between patient
characteristics and TDLU measurements are shown in Table 2. All TDLU measurements declined with
increasing age, irrespective of case-control status. TDLU count/mm2 was also inversely associated
with BMI, though only significantly associated among control patients (p = 0.04). No statistically
significant associations were observed between any of the tumor characteristics investigated and
TDLU count/mm2 or span. Among control patients, acini count/TDLU was significantly higher among
patients with regional/distant disease compared with those with localized disease (p = 0.03).
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Table 2. Relationship between patient and tumor characteristics and TDLU measurements among ER-positive case and control breast cancer patients treated
with tamoxifen.
Case patients (n = 54) Control patients (n = 180)
TDLU Count/100 mm2 TDLU Span& (Microns) Acini Count/TDLU& TDLU Count/100 mm2 TDLU Span& (Microns) Acini Count/TDLU&
Median IQR p Value Median IQR p Value Median IQR p Value Median IQR p Value Median IQR p Value Median IQR p Value
All patients 5.9 1.3–10.0 416 284.0–665.5 21 14.0–42.3 7.0 2.7–16.3 465 312.5–631.5 24 11.5–46.5
Age at diagnosis (years) <0.01 0.01 0.01 <0.01 <0.01 <0.01
<50 14.7 8.7–27.8 677 409.8–928.5 43 30.0–65.0 11.4 5.5–21.7 594 477.0–768.5 40 24.3–56.8
50–59 7.5 3.6–22.9 406 331.5–606.5 23 12.5–49.0 12.5 4.6–25.5 487 368.0–655.0 28 15.0–51.0
>59 3.5 1.0–7.5 348 245.0–465.0 18 12.0–22.5 3.9 2.0–9.1 342 271.0–496.0 14 8.5–25.5
Race 0.03 0.09 0.09
White 5.9 1.3–10.0 − 416 284.0–665.5 − 21 14.0–42.3 − 6.8 2.7–15.0 453 307.0–628.5 24 11.5–46.0
Non-white 0.0 − 0 − 0 − 27.8 13.9–44.0 650 515.8–929.3 50 33.5–61.8
Smoking status at baseline 0.16 0.61 0.51 0.18 0.06 0.14
Never 3.8 1.0–9.5 399 269.5–606.5 19 12.0–40.0 8.3 2.7–18.6 512 328.5–687.3 25 11.5–53.5
Ever 8.3 2.5–10.6 421 331.5–671.0 22 14.5–43.5 6.2 2.8–11.3 425 299.5–575.5 20 10.5–40.5
Missing
BMI at diagnosis (kg/m2) 0.57 0.27 0.19 0.04 0.72 0.33
<25 7.1 2.3–11.1 380 227.5–448.0 16 8.0–27.0 8.0 4.6–19.5 518 307.0–675.5 25 14.0–53.5
25 to <30 4.7 1.4–9.2 353 245.0–494.5 16 12.0–21.0 7.4 2.8–15.6 422 298.0–614.5 20 10.5–51.0
≥30 3.9 0.9–9.9 432 308.8–648.3 23 16.0–44.8 6.1 2.1–10.6 477 323.0–655.0 28 11.5–40.5
Missing
Hormone therapy use at baseline 0.21 0.88 0.76 0.70 0.19 0.34
Non-user 3.3 0.6–9.5 399 239.0–729.0 22 8.0–40.0 7.6 3.1–18.6 474 334.0–675.5 25 11.5–51.5
Current user 6.7 3.6–10.0 418 341.5–606.5 20 16.0–41.0 7.0 2.6–15.0 477 317.0–640.5 24 13.5–50.0
Former user 9.2 1.3–21.8 450 286.0–671.0 31 14.0–53.0 5.3 2.4–18.5 358 271.0–605.5 15 10.5–34.0
SEER summary stage at diagnosis 0.97 0.75 0.77 0.16 0.05 0.03
Localized 5.8 0.9–21.8 380 237.3–686.0 20 11.0–40.5 5.6 2.5–14.8 440 284.8–614.3 18 10.5–45.5
Regional/distant/unknown 6.0 1.5–9.7 422 325.3–610.0 21 14.0–44.8 8.4 3.2–17.4 487 344.5–658.5 28 14.5–51.0
Year of Diagnosis 0.67 0.21 0.40 0.62 0.09 0.25
1990–1996 5.8 1.6–22.9 495 348.0–688.0 23 16.0–63.5 6.9 3.1–18.6 425 297.0–587.0 20 11.3–39.3
1997–2000 5.1 1.0–9.7 399 245.0–606.5 19 12.0–36.0 6.5 2.5–14.7 477 334.0–655.0 24 13.5–51.5
2001–2008 7.1 1.0–10.0 320 275.8–666.3 17 13.3–29.3 7.7 4.2–16.3 552 349.0–683.0 35 13.0–46.0
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Table 2. Cont.
Case patients (n = 54) Control patients (n = 180)
TDLU Count/100 mm2 TDLU Span& (Microns) Acini Count/TDLU& TDLU Count/100 mm2 TDLU Span& (Microns) Acini Count/TDLU&
Median IQR p Value Median IQR p Value Median IQR p Value Median IQR p Value Median IQR p Value Median IQR p Value
Progesterone Receptor 0.50 0.76 0.92 0.64 0.91 0.91
Negative 5.4 1.3–9.7 424 331.5–497.0 19 14.5–27.5 8.2 3.4–24.1 468 302.0–640.50 26 15.0–41.5
Positive 7.1 1.6–11.1 411 269.5–684.0 22 12.0–49.0 7.0 2.7–14.9 466 318.0–627.3 24 11.5–50.5
Missing
Tumor Size (cm) 0.86 0.21 0.24 0.61 0.07 0.06
≤2 6.7 2.7–21.2 421 282.0–683.0 19 14.5–46.0 6.7 3.1–14.8 449 298.0–615.5 23 11.0–45.0
>2 4.7 0.7–9.6 399 269.5–671.0 22 12.0–41.0 8.3 2.6–18.7 542 346.0–655.0 29 17.0–51.5
Missing
Tumor differentiation 0.22 0.55 0.55 0.56 0.58 0.80
Well differentiated 0.0 − 0 − 0 − 8.0 4.6–21.4 446 304.8–596.3 23 12.8–43.3
Moderately differentiated 7.3 3.1–14.6 399 245.0–671.0 19 12.0–46.0 7.3 2.5–15.0 518 303.3–676.8 25 11.5–51.5
Poorly differentiated 3.6 1.0–10.0 436 320.0–648.8 22 15.3–42.3 6.1 2.8–17.4 431 334.0–589.0 24 14.0–39.5
Missing
Duration of tamoxifen use, mo 0.24 0.52 0.17 0.46 0.06 0.16
≤52 5.1 1.0–21.2 411 2860–729.0 23 16.0–49.0 9.4 3.2-19.9 558 396.0–745.0 29 16.0–54.5
53 to 61 1.5 1.0–4.2 354 245.0–448.0 15 9.5–21.5 7.3 2.9–13.3 429 304.0–606.5 24 11.5–45.5
>61 8.7 6.0–9.7 458 319.0–513.5 20 12.0–31.0 5.2 2.5–18.8 465 297.0–614.5 20 11.5–41.0
IQR: interquartile range; TDLU: terminal duct lobular unit and &: among patients with TDLUs observed. p-values were estimated using Kruskal–Wallis tests and were computed excluding
the missing categories. p-values <0.05 are highlighted in bold font. Tertiles based on the distribution among control patients.
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3.3. Association between MD and Measures of TDLU Involution
Relationships were observed between TDLU and MD measures among control patients, for whom
positive associations were observed with baseline % MD (TDLU count/mm2: p = 0.03; TDLU span:
p = 0.03 and median acini count/TDLU: p < 0.01; Table 3). Similar patterns of association with baseline %
MD were observed for case patients, although associations with TDLU count and acini/TDLU were not
statistically significant and only TDLU span showed a statistically significant positive association with
baseline % MD (p < 0.01). Positive associations were also observed for relationships of TDLU metrics
with baseline absolute dense area, though statistically significant associations were only observed
among case patients for TDLU span (p < 0.01) and acini count/TDLU (p < 0.01). Inverse associations
between TDLU measurements and baseline non-dense area were largely restricted to control patients.
With respect to TDLU associations with follow-up % MD (post-tamoxifen), patterns of association
appeared similar to those observed for baseline % MD for both cases and controls; however, strengths
of associations were attenuated for all TDLU measures (Table 3).
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Table 3. Relationship between TDLU measurements and baseline and follow-up MD measurements among ER-positive case and control patients treated with tamoxifen.
TDLU measure Baseline Density (%) Baseline Dense Area (cm2) Baseline Non-Dense Area (cm2) Follow-Up Density (%) Breast Density Change (%)
N Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Case patients
TDLU count/100 mm2
0 6 26.0 (18.8, 33.2) 43.2 (30.5, 56.0) 121.1 (94.6, 147.7) 17.1 (11.5, 22.7) −8.5 (−15.3, −1.7)
0–≤4.7 18 17.7 (14.2, 21.3) 31.5 (24.9, 38.0) 151.8 (134.0, 169.6) 18.4 (14.9, 21.9) 0.2 (−3.9, 4.2)
>4.7–≤13 19 26.1 (21.5, 30.6) 30.7 (24.0, 37.5) 100.8 (85.6, 116.0) 22.8 (18.8, 26.9) −3.0 (−7.3, 1.3)
>13 11 32.0 (23.1, 40.8) 55.6 (39.6, 71.6) 112.2 (84.0, 140.4) 26.3 (18.6, 34.0) −4.6 (−12.1, 2.9)
p-value for trend 0.15 0.61 0.11 0.07 0.75
Median TDLU span (microns)
0–≤352 18 17.8 (14.4, 21.2) 26.5 (21.2, 31.7) 133.7 (114.6, 152.9) 19.3 (15.8, 22.7) 1.5 (−2.4, 5.4)
>352–≤578 15 26.3 (22.0, 30.6) 35.4 (29.1, 41.8) 109.3 (91.1, 127.5) 23.1 (19.1, 27.1) −3.6 (−7.7, 0.5)
>578 15 33.6 (26.7, 40.5) 57.1 (45.7, 68.6) 114.1 (87.9, 140.3) 25.8 (19.9, 31.8) −6.5 (−12.3, -0.7)
p-value for trend <0.01 <0.01 0.31 0.19 0.02
Median acini count per TDLU
0–≤15 15 20.5 (16.2, 24.8) 27.4 (21.3, 33.5) 121.6 (100.8, 142.4) 20.2 (16.2, 24.2) −0.5 (−5.0, 4.1)
>15–≤36.5 19 22.7 (18.6, 26.7) 33.3 (27.3, 39.2) 122.0 (103.4, 140.6) 21.8 (18.1, 25.5) −1.3 (−5.4, 2.8)
>36.5 14 33.1 (25.7, 40.5) 57.2 (45.4, 69.0) 116.2 (88.9, 143.6) 25.7 (19.7, 31.8) −6.1 (−12.3, 0.0)
p-value for trend 0.08 <0.01 0.85 0.35 0.21
Control patients
TDLU count/100 mm2
0 9 26.7 (19.7, 33.6) 30.8 (20.6, 41.1) 103.7 (80.9, 126.5) 22.5 (16.4, 28.6) −6.2 (−12.6, 0.2)
0–≤4.7 57 23.9 (21.1, 26.7) 33.5 (28.9, 38.0) 110.8 (100.8, 120.9) 19.6 (17.2, 22.0) −5.2 (−7.9, −2.5)
>4.7–≤13 57 30.5 (27.5, 33.5) 40.6 (35.8, 45.4) 97.8 (88.8, 106.8) 25.9 (23.3, 28.6) −4.5 (−7.1, −1.9)
>13 57 31.5 (28.3, 34.8) 39.5 (34.4, 44.5) 84.9 (75.9, 93.9) 22.4 (19.8, 25.1) −9.4 (−12.2, −6.6)
p-value for trend 0.03 0.15 0.02 0.36 0.09
Median TDLU span (microns)
0–≤352 57 25.7 (22.6, 28.8) 34.3 (29.4, 39.3) 105.5 (95.5, 115.5) 20.6 (17.9, 23.3) −6.0 (−8.9, −3.1)
>352–≤578 57 28.3 (25.4, 31.4) 37.3 (32.5, 42.1) 94.2 (85.4, 102.9) 23.5 (20.8, 26.1) −4.6 (−7.3, −1.9)
>578 57 32.8 (29.6, 35.9) 41.6 (36.6, 46.5) 87.7 (79.4, 96.0) 24.7 (22.0, 27.3) −8.5 (−11.2, −5.9)
p-value for trend 0.03 0.17 0.07 0.17 0.18
Median acini count per TDLU
0–≤15 57 24.1 (21.3, 27.0) 32.8 (28.2, 37.4) 109.7 (100.0, 119.4) 20.2 (17.6, 22.7) −4.8 (−7.6, −2.0)
>15–≤36.5 56 29.1 (26.1, 32.1) 38.1 (33.3, 42.9) 93.7 (85.2, 102.3) 23.3 (20.7, 25.9) −5.9 (−8.6, 3.2)
>36.5 57 34.1 (30.8, 37.4) 42.7 (37.6, 47.9) 83.8 (75.6, 92.1) 25.5 (22.7, 28.3) −8.6 (−11.4, −5.9)
p-value for trend <0.01 0.06 <0.01 0.06 0.07
Breast density change was defined as (follow-up % density-baseline % density) such that negative value indicates a decrease in % density over follow-up. Analysis of covariance (ANCOVA)
models were used, adjusting for age, stage, year of diagnosis and BMI. MD measures were square-root transformed to better approximate normal distributions. For ease of interpretation,
back transformed least square means, with calculated corresponding 95% confidence intervals, are presented by tertiles of TDLU measures. Tertiles of TDLU measures were defined
according to distributions of measures among control patients. p-values <0.05 are highlighted in bold font.
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3.4. Influence of TDLU Measurements on the Relationship between MD Decline and Reduced Risk of Breast
Cancer-Specific Death among ER-positive Patients Treated with Tamoxifen
The relationship between a 10% or greater reduction in % MD (between baseline and follow-up
mammograms) and reduced risk of breast cancer-specific death among this analytic population of
patients with slides available for lobule involution evaluation was statistically significant (OR: 0.41 and
95% CI: 0.18, 0.92; Table 4). This finding was consistent with our previously reported association in all
case-control patients (i.e., including those both with and without available benign slides for analysis
(OR: 0.42 and 95% CI: 0.22, 0.80 [6])). Similar associations were observed after additional adjustment
for TDLU count/mm2 (OR: 0.41 and 95% CI: 0.18, 0.94), TDLU span (OR: 0.34 and 95% CI: 0.14, 0.84) or
median acini count/TDLU (OR: 0.33 and 95% CI: 0.13, 0.81) and when all the TDLU measures were
included in the model (OR: 0.33 and 95%CI 0.13, 0.81; Table 4). In analyses stratified by the median of
each TDLU metric, the patterns of association between density reduction and reduced risk of breast
cancer-specific death persisted, though confidence limits were wide likely due to sparse numbers
in TDLU subgroups (Supplementary Table S3). Although there was some suggestion of a stronger
protective effect of MD decline among those with higher baseline TDLU counts, a test for interaction
between TDLU count/mm2 and change in percent MD was null (p-interaction = 0.52). In sensitivity
analysis, additional adjustment for duration of tamoxifen use and smoking did not substantially alter
the observed associations (data not shown).
Table 4. Relationships between MD decline* and breast cancer-specific death before and after adjustment
for TDLU measurements among ER-positive patients treated with tamoxifen.
OR (95% CI)
Base model $ 0.41 (0.18, 0.92)
Base model adjusted for TDLU count/mm2 0.41 (0.18, 0.94)
Base model adjusted for TDLU span & 0.34 (0.14, 0.84)
Base model adjusted for acini count/TDLU & 0.33 (0.13, 0.81)
Base model adjusted for TDLU count, span and acini/TDLU 0.33 (0.13, 0.81)
CI: confidence interval, MD: mammographic density, OR: odds ratio, TDLU: terminal duct lobular unit.
* Mammographic density decline defined as a ≥ 10% decrease between baseline and follow-up mammograms: ≥10%
(n = 9 cases, n = 61 controls); <10% (reference group: n = 45 cases, n = 119 controls). $ Base model adjusted for age,
stage, year of diagnosis, follow-up time (all as categorical variables). & among women with observed TDLUs.
4. Discussion
Decline in MD has been linked to improved outcomes among women with ER-positive breast
cancers treated with tamoxifen, as previously reported in this cohort [6]. Given that higher MD and
less TDLU involution are correlated, yet independent measures of breast cancer risk, we investigated
whether measurement of pre-diagnostic lobular involution modifies the prognostic significance of
MD decline among patients receiving adjuvant tamoxifen. Our results show that reduced levels of
involution, assessed as higher TDLU counts/mm2, larger TDLU span, or a greater number of acini
counts/TDLU, did not significantly alter the relationship between MD decline and reduced risk of
breast cancer-specific death among this population of ER-positive breast cancer patients treated with
tamoxifen. We identified TDLUs in most of the breast cancer specimens, irrespective of patient case or
control status. Consistent with prior reports [28], we also found relationships between TDLU metrics
and breast cancer risk factors, which followed expected patterns, including inverse associations with
age, and a positive relationship with baseline MD.
Lobule involution, a histologic measure, has been hypothesized to be reflected radiologically
in MD, a breast cancer risk marker for which the underlying biology is not fully elucidated [28].
A recent analysis that examined TDLUs among 1115 women who had serial biopsies over time from
the Mayo Benign Breast Disease (BBD) Cohort, highlighted the importance of persistent TDLUs over
time as a breast cancer biomarker [19]. In that study, the authors showed that no progression of the
involution process, i.e., persistent TDLUs, between the initial and subsequent biopsies was associated
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with a larger increase in risk of breast cancer development compared with women who experienced
progression of lobular involution between biopsies [19]. Thus, while progression of involution over
time may be protective in women, delayed involution (persistent TDLUs) may contribute to breast
cancer development, supporting the importance of understanding the relevance of the degree of lobular
involution at the time of and subsequent to breast cancer diagnosis.
Compared to studies that have examined the relationships between TDLU involution and breast
cancer risk, less is known about the role of involution at diagnosis. Herein, we report for the first time
that levels of involution at diagnosis did not significantly alter the relationship between MD decline
and reduced risk of breast cancer-specific death among ER-positive breast cancer patients treated with
tamoxifen. Our results raise interesting mechanistic questions about the observed association between
density decline and improved breast cancer outcomes with tamoxifen. The original observation of this
association was reported in the IBIS (International Breast Cancer Intervention Study)-I chemoprevention
trial in which preventive therapy with tamoxifen was associated with a lower risk of incident breast
cancer, suggesting a possible direct effect on at-risk breast epithelium [20]. Recent data using novel
volumetric MD measurements suggest that treatment with aromatase inhibitors may also produce
declines in MD [29], although the prognostic impact remains unclear in the prevention and adjuvant
settings. Given that breast cancer deaths are attributable almost exclusively to metastatic disease, it is
unlikely that the mechanisms mediating the prognostic effect of tamoxifen-related MD decline are
fully related to effects on the breast. Previously, we suggested that declines in density might represent
a biosensor of tamoxifen effectiveness, potentially related to bioavailability of potent tamoxifen
metabolites [5]. How tamoxifen treatment alters breast fibroglandular pathology, as reflected in MD
decline at the radiological level, is not well understood and requires further studies examining breast
tissue both pre- and post-tamoxifen treatment, to fully investigate histological biomarkers of MD
change in this setting. Analysis of murine models that demonstrate tamoxifen associated declines in
mammary fibroglandular tissue composition may uncover molecular mechanisms underlying these
associations [11]. Additional studies investigating relationships between MD decline and tamoxifen
metabolism, and future window of opportunity clinical studies with pre- and post-treatment tissues,
will be crucial in understanding these relationships.
Although associations of TDLU involution with age and MD were as expected in our study, we observed
a higher proportion of pathology specimens containing TDLUs than prior reports [24,30–32]. In contrast
to prior reports [31], our population differed in that it was nearly exclusively white and included the
highest proportion of obese women. Further, our analyses used sections from tissue blocks adjacent to the
tumor, whereas the proximity of tissue sections in relation to cancers may have differed in other reports.
Limitations of this study included the sample size, which led to limited statistical power, particularly
for stratified analysis of MD change. An additional limitation includes the absence of information on
reproductive factors including menopausal status and parity, two factors that are both related to MD
and TDLU involution [14]. Further, we were unable to examine changes in TDLU involution over time,
following tamoxifen treatment. The strengths of this study include the use of benign breast tissue sections to
examine lobular involution, contributing to the characterization of histology of benign tissue surrounding
invasive breast cancer. A further strength was the use of reproducible standardized metrics to assess TDLU
involution, along with quantitative assessment of MD and MD decline measurements. An additional
strength includes the integration of histological data from archival tissue with the radiological data from
mammograms into this retrospective cohort of breast cancer survivors, which aims to identify factors
associated with breast cancer prognosis.
In conclusion, our findings suggest that TDLU involution levels at breast cancer diagnosis were
unrelated to tamoxifen effectiveness in the adjuvant setting. MD decline following adjuvant tamoxifen
initiation was associated with reduced risk of breast cancer-specific death, and thus acting as potential
biosensor of tamoxifen effectiveness, irrespective of pre-tamoxifen treatment TDLU involution levels.
Future studies to examine change in TDLU involution over time following tamoxifen treatment in
J. Clin. Med. 2019, 8, 1868 13 of 15
the adjuvant and breast cancer prevention setting may provide useful information with regard to
predicting favorable responses.
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